Tumor Cell Dormancy Sustained by Extracellular Matrix Mechanical Signaling

Abstract

Tumor cell dormancy is a clinically important state in which disseminated malignant cells remain viable but exhibit limited proliferation for prolonged periods before progressing to overt metastatic disease. Increasing evidence indicates that dormancy is not determined solely by tumor-intrinsic programs or immune surveillance. Mechanical signals generated by the extracellular matrix, including matrix stiffness, tension, ligand presentation, topography, and interstitial pressure, can actively regulate whether residual tumor cells remain quiescent or resume growth. Through integrin adhesion complexes, focal adhesion kinase, Src-family kinases, Rho-associated protein kinase, the Hippo pathway, YAP/TAZ, mechanosensitive ion channels, and cytoskeletal remodeling, the matrix establishes a biomechanical context that influences cell-cycle entry, survival, metabolism, stemness, and therapy resistance. A compliant, organized, or basement-membrane-like niche may sustain dormancy, whereas fibrosis, collagen cross-linking, inflammation, vascular remodeling, and increased tissue rigidity may provide permissive signals for metastatic awakening. Clinically, these mechanisms help explain late recurrence, organ-specific metastatic patterns, and the persistence of minimal residual disease despite apparently successful treatment. Mechanical biomarkers and interventions that normalize or disrupt pathological matrix signaling may complement endocrine, targeted, immune, and cytotoxic therapies. Translation remains challenging because matrix properties vary between organs, lesions, and stages of disease, and because suppressing mechanical signaling without impairing tissue repair or host defense requires careful therapeutic selectivity.

Introduction

Metastatic relapse years or decades after treatment is a defining challenge in oncology. Disseminated tumor cells may leave the primary lesion early, enter distant organs, and persist in a nonproliferative or slowly cycling state. Because conventional chemotherapy and many targeted agents preferentially affect actively dividing cells, dormant cells can remain clinically undetectable and later generate recurrent disease. Dormancy therefore represents both a biological adaptation and a therapeutic problem involving tumor cells, stromal cells, immune populations, blood vessels, and the extracellular matrix.

The extracellular matrix is a dynamic signaling system rather than a passive scaffold. It consists of collagens, laminins, fibronectin, proteoglycans, glycoproteins, and matricellular proteins that define tissue architecture and regulate adhesion, growth factor availability, migration, and mechanical force transmission. Matrix stiffness and tensile stress are influenced by collagen deposition, enzymatic cross-linking, proteolysis, cellular contraction, hydration, and interstitial fluid pressure. These features can change during aging, wound healing, chronic inflammation, fibrosis, and tumor progression. Dormant cancer cells continuously interpret this mechanical environment through membrane receptors and cytoskeletal networks, creating a functional link between tissue biomechanics and metastatic behavior.

Epidemiology / Disease Burden

The exact prevalence of dormant disseminated tumor cells is difficult to measure because dormancy is usually clinically silent and lacks a universally standardized diagnostic definition. Nevertheless, late recurrence is well documented in breast cancer, prostate cancer, melanoma, renal cell carcinoma, colorectal cancer, and several hematologic malignancies. In hormone receptor-positive breast cancer, recurrence risk can persist for many years after completion of adjuvant endocrine therapy, supporting the concept that residual cells may survive in restrained states. Prostate cancer may also recur after long intervals following apparently definitive local treatment. Melanoma and renal cell carcinoma demonstrate marked heterogeneity in the timing of metastatic relapse, consistent with variable interactions between disseminated cells and organ-specific niches.

The burden of dormant disease extends beyond recurrence statistics. Persistent tumor cells can acquire therapy resistance, alter their metabolism, evade immune recognition, and adapt to changing host physiology. Their eventual reactivation contributes to incurable metastatic disease, increased treatment toxicity, functional decline, and healthcare utilization. Because current surveillance generally detects macroscopic growth rather than dormant cell populations, the clinical burden is likely underestimated.

Pathophysiology

Mechanical regulation of dormancy begins with the physical properties of the extracellular matrix. A compliant matrix can limit integrin clustering and reduce maturation of focal adhesions, thereby decreasing signaling through focal adhesion kinase, Src, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase. Reduced force transmission may restrain actomyosin contractility and maintain low activity of transcriptional regulators associated with proliferation. In contrast, a stiff and highly cross-linked matrix promotes integrin engagement, cytoskeletal tension, nuclear deformation, and activation of YAP and TAZ. These factors can induce proliferative, survival, and stemness-associated gene programs and may support escape from dormancy.

Matrix composition is as important as stiffness. Laminin-rich basement-membrane environments can provide survival signals while retaining cells in a quiescent phenotype in some tissue contexts. Fibronectin deposition, collagen remodeling, and exposure of cryptic matrix fragments may instead activate inflammatory and motility pathways. The effects are highly dependent on tumor type, organ site, receptor expression, and the availability of soluble mediators. Integrins such as beta-1, beta-3, and alpha-v-containing complexes can connect matrix ligation to survival signaling, while discoidin domain receptors respond directly to fibrillar collagen. Mechanosensitive channels, including PIEZO1, may translate membrane tension into calcium-dependent changes in migration, metabolism, and cell-cycle control.

The relationship between mechanics and dormancy is bidirectional. Dormant cells can modify their surrounding matrix through secretion of proteases, lysyl oxidase-related enzymes, and extracellular vesicles, while stromal fibroblasts can create a protective niche through collagen organization and deposition. Cancer-associated fibroblasts may generate either restrictive or permissive mechanical environments depending on their phenotype and anatomical location. Immune cells, endothelial cells, adipocytes, and pericytes further regulate matrix turnover, vascular permeability, oxygenation, and inflammatory signaling. Hypoxia and nutrient limitation can reinforce quiescence, but persistent hypoxia may also select for cells capable of surviving in hostile conditions and later responding to reoxygenation or vascular remodeling.

Risk Factors

Factors associated with mechanical maintenance or escape from dormancy include extensive fibrosis, chronic inflammation, aging-related matrix cross-linking, obesity-associated stromal remodeling, tissue injury, and altered vascular permeability. Tumor characteristics such as high plasticity, stem-like phenotypes, epithelial-to-mesenchymal transition programs, and expression of specific integrins may increase the ability of disseminated cells to adapt to diverse niches. Inadequate local control of the primary tumor, lymphovascular invasion, and a high burden of circulating or disseminated tumor cells increase the probability that dormant populations are established. Treatment-related tissue injury may also alter matrix composition and inflammatory signaling, although the clinical consequences vary by cancer type and therapy.

Clinical Features

Dormancy itself usually produces no symptoms and cannot be recognized through routine physical examination. The clinically relevant presentation is often delayed recurrence in an organ that was apparently free of disease after definitive therapy. Relapse may arise in bone, liver, lung, brain, lymph nodes, or soft tissue, with manifestations determined by the metastatic site. A prolonged disease-free interval does not necessarily indicate eradication. Conversely, the presence of disseminated tumor cells does not invariably predict imminent relapse because many remain controlled by local niche signals or immune surveillance.

Clinicians should consider dormant disease when counseling patients about long-term risk, interpreting late biochemical or radiographic abnormalities, and evaluating recurrence after prolonged remission. The timing of relapse, molecular subtype, initial stage, treatment response, and pattern of metastatic spread should be integrated rather than relying on one biomarker. Mechanical niche biology is currently more useful for understanding risk and therapeutic resistance than for making a standalone clinical diagnosis.

Diagnosis

No routine clinical test directly measures matrix-supported tumor dormancy. Circulating tumor DNA, circulating tumor cells, molecular residual disease assays, and tissue-based detection of disseminated tumor cells may identify persistent disease in selected settings, but sensitivity, specificity, and prognostic thresholds differ among cancers. Imaging can detect established metastatic growth but generally cannot distinguish dormant viable cells from fibrosis, scar tissue, or microscopic residual disease. Research approaches include spatial transcriptomics, multiplex imaging, atomic force microscopy, second-harmonic generation microscopy, and computational mapping of collagen architecture. These methods may eventually connect matrix mechanics with relapse risk, but they require validation, standardization, and prospective clinical correlation.

Diagnostic evaluation should therefore follow disease-specific guidelines. Pathological confirmation of suspected recurrence remains important when feasible, particularly when treatment selection depends on receptor status or genomic evolution. A new metastatic lesion may differ biologically from the primary tumor, and reassessment can reveal changes in endocrine receptors, HER2 expression, immune markers, or actionable genomic alterations.

Treatment & Management

Current management is directed primarily at eliminating residual malignant cells, preventing proliferation, and treating established recurrence. Endocrine therapy, HER2-directed therapy, androgen-receptor pathway inhibition, cytotoxic chemotherapy, immunotherapy, and molecularly targeted agents may suppress or eradicate tumor populations depending on tumor biology. Adjuvant treatment decisions should account for recurrence risk, patient comorbidity, expected benefit, toxicity, and guideline-defined biomarkers. Because dormant cells are often nondividing, prolonged treatment or maintenance strategies may be necessary in selected diseases, although indefinite therapy is not appropriate for every patient.

Matrix-directed treatment is an emerging adjunct rather than an established standard. Experimental approaches include inhibition of lysyl oxidase-mediated collagen cross-linking, modulation of focal adhesion kinase or Src signaling, targeting integrin activity, reducing pathological fibroblast activation, and regulating YAP/TAZ or Rho-associated kinase pathways. Matrix normalization may improve drug penetration and immune-cell access, but excessive matrix depletion can destabilize tissue architecture, impair vascular integrity, or alter immune responses. A further concern is that forcing dormant cells into proliferation without simultaneous effective tumor killing could increase relapse risk. Mechanical interventions should therefore be developed alongside, and not independently of, cytotoxic, targeted, or immune therapies.

Recent Advances / Emerging Therapies

Recent research increasingly uses organoid systems, engineered three-dimensional matrices, microfluidic platforms, and patient-derived xenografts to separate biochemical from mechanical cues. These models show that matrix stiffness can alter drug sensitivity, lineage plasticity, and the balance between quiescence and proliferation. Single-cell and spatial methods are identifying mechanically distinct subpopulations within the same lesion, including cells positioned near vessels, nerves, basement membranes, or fibrotic boundaries. Such work supports a model in which dormancy is heterogeneous and reversible rather than a uniform cellular state.

Potential future strategies include combining standard systemic therapy with selective inhibitors of mechanotransduction, using matrix-associated biomarkers to identify patients at high risk of late recurrence, and applying intermittent treatment schedules that address both quiescent and proliferative states. Therapeutic antibodies, degradable biomaterials, and stromal reprogramming approaches may eventually modify pathological niches without removing essential structural matrix. However, clinical development must establish whether a mechanical target is tumor-selective, whether inhibition reaches disseminated cells in relevant organs, and whether pharmacodynamic changes can be measured safely in patients.

Guideline Recommendations

Major oncology guidelines do not currently recommend routine matrix-mechanical testing or dedicated anti-mechanotransduction therapy for dormant disease outside clinical trials. Clinicians should follow disease-specific recommendations for staging, molecular profiling, adjuvant systemic therapy, surveillance, and management of recurrence. Long-term follow-up is important for cancers with recognized late-recurrence risk, and treatment decisions should be revisited when new clinical, pathological, or molecular information becomes available. Enrollment in well-designed clinical trials is appropriate for patients with measurable molecular residual disease, high-risk features, or recurrent disease that may be affected by investigational stromal or mechanical targets.

Patient counseling should explain that a disease-free interval reduces but does not eliminate recurrence risk and that surveillance schedules are based on evidence for the specific malignancy. Lifestyle measures, management of metabolic and inflammatory comorbidities, vaccination where appropriate, and prompt assessment of concerning symptoms support general cancer care, although none should be presented as proven methods for eliminating matrix-maintained dormant cells.

Conclusion

Extracellular matrix mechanics provide a biologically plausible and increasingly well-supported framework for understanding how disseminated tumor cells survive, remain quiescent, and later reactivate. Matrix stiffness, architecture, ligand composition, force transmission, and stromal remodeling influence integrin signaling, cytoskeletal tension, mechanosensitive channels, YAP/TAZ activity, metabolism, and immune interactions. These processes help explain late recurrence and the limited effectiveness of therapies directed only at actively cycling tumor cells. At present, clinical care should remain guided by tumor-specific evidence and established oncology recommendations, while mechanical biomarkers and niche-directed therapies are evaluated in rigorous trials. Future progress will depend on integrating biomechanical measurements with molecular profiling, immune characterization, and longitudinal assessment of minimal residual disease. Such an approach may ultimately enable treatment strategies that not only suppress visible cancer but also prevent dormant cells from receiving the mechanical signals required for metastatic awakening.